Covered recipient · General Payments record
NAUMAN MOAZZAM
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$83,860.35
- Reported across 199 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,569.47 | 75 |
| Consulting Fee | $1,130.00 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| TAIHO ONCOLOGY, INC. | $1,130.00 | 1 |
| Celgene Corporation | $205.92 | 16 |
| Daiichi Sankyo Inc. | $172.39 | 12 |
| Janssen Biotech, Inc. | $119.37 | 5 |
| TerSera Therapeutics LLC | $115.89 | 4 |
| Sumitomo Pharma America, Inc. | $97.58 | 4 |
| PFIZER INC. | $80.17 | 4 |
| GlaxoSmithKline, LLC. | $76.74 | 3 |
| ERBE USA INC | $75.00 | 1 |
| ABBVIE INC. | $69.06 | 3 |
| Mirati Therapeutics, Inc. | $65.23 | 3 |
| Astellas Pharma US Inc | $50.58 | 2 |
| Acerta Pharma LLC | $42.98 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $42.39 | 2 |
| EISAI INC. | $41.15 | 2 |
| GENZYME CORPORATION | $36.25 | 1 |
| Genmab U.S., Inc. | $30.20 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $29.45 | 1 |
| Exelixis Inc. | $26.77 | 1 |
| Genentech USA, Inc. | $26.59 | 1 |
| Gilead Sciences, Inc. | $26.45 | 1 |
| Iovance Biotherapeutics, Inc. | $24.04 | 1 |
| E.R. Squibb & Sons, L.L.C. | $22.98 | 1 |
| Ipsen Biopharmaceuticals, Inc | $22.13 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.98 | 1 |
| Ferring Pharmaceuticals Inc. | $17.76 | 1 |
| TACTILE SYSTEMS TECHNOLOGY INC | $17.66 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $16.76 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (76)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.